Last week ended with another Friday night blitz of biotech S-1s as a fresh wave of new offerings forms to crash into Nasdaq. Entering the Wall Street spotlight now is one transatlantic operation that is out to develop a new class of meds, a Dallas biotech with a Phase III kidney cancer drug and a startup that in-licensed its lead drug from Novartis.
They are all oncology focused, highlighting the big money that continues to pour into all things cancer related.
Each of these 3 biotechs has been partial to the classic biotech startup game plan, where you flag incoming collaborations with the biggest names you can find to work with — while often staying mum about the cash involved and/or keeping the details about their lead programs under wraps.
Oncology, after all, is an intensely competitive field. But come the S-1s, secrets must be spilled.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.Free Subscription